Effects of silymarin supplementation in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study;Az antioxidáns flavonoid silymarin szupplementációja hatásának placebokontrollos vizsgálata PEG-IFN + ribavirin antivirális kezelésben részesülo krónikus C-hepatitises betegekben

Orvosi Hetilap

Volumn 150, Issue 2, 2009, Pages 73-79

  Pár, Alajos ^a,e   Roth, Erzsébet ^b   Miseta, Attila ^c   Hegedüs, Géza ^d   Pár, Gabriella ^a   Hunyady, Béla ^a   Vincze, Áron ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Sebészeti Oktató És Kutató Intézet   (Hungary)

^c Laboratóriumi Medicina Intézet   (Hungary)

^d I sz Belgyógyászati és Gasztroenterológiai Osztály   (Hungary)

^e NONE   (Hungary)

Author keywords

Hepatitis C; Oxidative stress; Silymarin

Indexed keywords

ALANINE AMINOTRANSFERASE; CATALASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MYELOPEROXIDASE; PEGINTERFERON; RIBAVIRIN; SILYMARIN; SUPEROXIDE DISMUTASE; VIRUS RNA; ANTIOXIDANT; ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; PEROXIDASE; PROTECTIVE AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GENOTYPE; HEMOLYSATE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS REPLICATION; VITAMIN SUPPLEMENTATION; AGED; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIOXIDANTS; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDASE; POLYETHYLENE GLYCOLS; PROTECTIVE AGENTS; RIBAVIRIN; RNA, VIRAL; SILYMARIN; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME;

EID: 60749103299     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28517     Document Type: Article

References (24)

1. Lauer, G. M., Walker, B. D.: Hepatitis C virus infection. New Engl. J. Med., 2001, 345, 41-52.
2. Pár, A., Kántor, I.: Prevalence of antibody to hepatitis C virus in blood donors, high risk groups and patients with liver diseases in Hungary. Acta Med. Hung., 1991, 48, 167-176.
3. De Maria, N., Colantoni, A., Fagiuoli, S. és mtsai: Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Rad. Biol. Med., 1996, 21, 291-295.
4. [4] Jain, S. K., Pemberton, P. W., Smith, A. és mtsai: Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J. Hepatol., 2002, 36, 805-811. (Pubitemid 35177411)
5. Barbaro, G., Di Lorenzo, G., Ribersani, M. és mtsai: Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J. Hepatol., 1999, 30, 774-782.
6. Boya, P., de la Pena, A., Beloqui, O. és mtsai: Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J. Hepatol., 1999, 31, 808-814.
7. Loguercio, C., Federico, A.: Oxidative stress in viral and alcoholic hepatitis. Free Rad. Biol. Med., 2003, 34, 1-10.
8. Larrea, E., Beloqui, O., Munoz-Navas, M-A. és mtsai: Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Rad. Biol. Med., 1998, 24, 1235-1241.
9. [9] Lai, M. M. C.: Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology, 2002, 122, 568-571 (Pubitemid 34117007)
10. Okuda, M., Li, K., Beard, M. R. és mtsai: Mitochondrial injury, oxidative stress and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology, 2002, 122, 366-375.
11. [11] Schuppan, D., Jia, J. D., Brinkhaus, B. és mtsa: Herbal products for liver diseases: a therapeutic challenge for the new millen nium. Hepatology, 1999, 30, 1099-1104. (Pubitemid 29458302)
12. Saller, R., Meier, R., Brignoli, R.: The use of silymarin in the treatment of liver diseases. Drugs, 2001, 61, 2035-2063.
13. [13] Mayer, K. É., Myers, R. P., Le, S. S.: Silymarin treatment of viral hepatitis: a systematic review. J. Viral. Hepat., 2005, 12, 559-567. (Pubitemid 41532486)
14. Pár A., R'th E., Rumi Gy. és mtsai: Oxidativ stress és antioxidáns védelem alkoholos májbetegsé gben és krónikus C hepatitisben. Orv. Hetil., 2000, 141, 1655-1659.
15. Pár, G., Rukavina, D., Podack, E. R. és mtsai: Decrease in CD3- negative-CD8dim+ and V?2/V?9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment on natural killer cell activity is associated with chronic hepatitis C virus infection. J. Hepatol., 2002, 37, 514-522.
16. Davis, G. L., Wong, J. B., McHutchison, J. G. és mtsai: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003, 38, 645-652.
17. Fehér J., Deák Gy., Müzes Gy. és mtsai: A silymarin (Legalon) therapia májvéd' hatása alkoholos májbetegségekben. Orv. Hetil., 1989, 130, 2723-2727.
18. Pár, A., Mézes, M., Németh, P. és mtsa: Effects of cianidanol on the blood lipid peroxide status in patients with chronic hepatitis. Int. J. Clin. Pharm. Res., 1985, 6, 389-392.
19. Pár, A., Király, T., Magyarlaki, T. és mtsai: Immunomodulatory effects of cyanidanol in chronic active hepatitis. Int. J. Immunother., 1985, 1, 27-33.
20. Pár, A., Szekeres-Bartho, J., Pácsa, S. és mtsa: Effect of cianidanol on natural killer cell activity in patients with chronic B viral hepatitis. Int. J. Clin. Pharm. Res., 1987, 7, 301-306.
21. [21] Tanamly, M. D., Tadros, F., Labeeb, S. és mtsai: Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig. Liv. Dis., 2004, 36, 752-759. (Pubitemid 41070597)
22. Gordon, A., Hobbs, D. A., Bowden, D. S. és mtsai: Effects of Silybum marianum on serum hepatitis C virus RNS, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J. Gastroenterol. Hepatol., 2006, 21, 275-280.
23. Polyak, S. J., Morishima, C., Shuart, M. C. és mtsai: Inhibition of T-cell infl ammatory cytokines, hepatocyte NF-B signaling, and HCV infection by standardized silymarin. Gastroenterology, 2007, 132, 1925-1936.
24. Ferenci, P., Scherzer, T. M., Hofer, A. és mtsai: Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to antiviral combination therapy. J. Hepatology, 2008, 48 (Suppl. 1, S28.